Hence, we hypothesize that in CRC, aberrant AS events lead to the formation of diverse Cyclin D-CDK4/6 complexes, rendering CDK4/6 inhibitors imprecise in targeting the truly active complexes, thus failing to elicit an effective therapeutic response. Here, CDK4 is linked to colorectal carcinoma.